Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

被引:3
|
作者
Liu, Limin [1 ]
Zhao, Xin [2 ]
Miao, Miao [1 ]
Zhang, Yanming [3 ,4 ]
Jiao, Wenjing [5 ]
Lei, Meiqing [6 ]
Zhou, Huifen [1 ]
Wang, Qingyuan [1 ]
Cai, Yifeng [7 ]
Zhao, Liyun [8 ]
Shangguan, Xiaohui [9 ]
Liu, Zefa [10 ]
Xu, Jinge [11 ]
Zhang, Fengkui [2 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Anemia Therapeut Ctr,Inst Hematol & Blood Dis Hos, Tianjin, Peoples R China
[3] Xuzhou Med Univ, Dept Hematol, Affiliated Huaian Hosp, Huaian, Peoples R China
[4] Second Peoples Hosp Huaian, Huaian, Peoples R China
[5] Xian Yang Cent Hosp, Dept Hematol, Xianyang, Peoples R China
[6] Cent South Univ, Dept Hematol, Haikou Municipal Peoples Hosp, Affiliated Haikou Hosp,Xiangya Sch Med, Haikou, Hainan, Peoples R China
[7] Nantong Univ, Dept Hematol, Affiliated Hosp, Nantong, Peoples R China
[8] People Hosp Xingtai, Dept Hematol, Xingtai, Peoples R China
[9] Fujian Med Univ, Dept Hematol, Longyan Hosp 1, Longyan, Peoples R China
[10] People Hosp Xinghua, Dept Hematol, Xinghua, Peoples R China
[11] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Xuzhou, Jiangsu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
国家重点研发计划;
关键词
severe aplastic anemia; immunosuppressive therapy; hematopoietic stem cell transplantation; first-line therapy; outcome; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; CYCLOSPORINE; GUIDELINES; MANAGEMENT; DIAGNOSIS; CHILDREN;
D O I
10.3389/fonc.2021.739561
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims This study aimed at comparing the efficacy and safety of severe aplastic anemia (SAA) cases that had met the criteria for SAA at the time of diagnosis (group A) with SAA that had progressed from non-SAA (NSAA) (group B), both undergoing first-line immunosuppressive therapy (IST). Additionally, group B was compared with SAA that had progressed from NSAA and who had been treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) (group C).</p> Methods We retrospectively compared 608 consecutive patients in group A (n = 232), group B (n = 229) and group C (n = 147) between June 2002 and December 2019. Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values, treatment-related mortality (TRM), secondary clonal disease, 5-year overall survival (OS) and failure-free survival (FFS) were indirectly compared between group A and group B, group B and group C.</p> Results Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values in group A was higher than in group B (65.24% vs. 40.54%, P < 0.0001; 23.33% vs. 2.25%, P < 0.0001); the same was true for group C (92.50% vs. 2.25%, P < 0.0001). The rate of relapse in group B was higher than in group C (P < 0.0001), but there were no differences in TRM and secondary clonal disease (P > 0.05). There were no differences in estimated 5-year OS between groups A and B (83.8% +/- 2.6% vs. 85.8% +/- 2.6%, P = 0.837), or between B and C (85.8% +/- 2.6% vs. 77.9% +/- 3.4%, P = 0.051). The estimated 5-year FFS in groups A and C was higher than for group B (57.1% +/- 3.3% vs. 39.7% +/- 3.4%, P < 0.001; 76.7% +/- 3.5% vs. 39.7% +/- 3.4%, P < 0.0001).</p> Conclusion These results indicate that IST is less effective in SAA progressing from non-SAA but allo-HSCT can improve outcomes.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia
    Zhang, Yuling
    Li, Yumiao
    Wu, Liangliang
    Zhou, Ming
    Wang, Caixia
    Mo, Wenjian
    Chen, Xiaowei
    Xu, Shilin
    Zhou, Ruiqing
    Wang, Shunqing
    Zhang, Yuping
    HEMATOLOGY, 2021, 26 (01) : 435 - 443
  • [2] Efficacy of hematopoietic stem cell transplantation in the treatment of children with non-severe aplastic anemia
    Zhang, Man
    Zhu, Guanghua
    Cai, Lixiao
    Yuan, Meng
    Wu, Runhui
    Jia, Chenguang
    Wang, Bin
    Zheng, Jie
    Ma, Jie
    Qin, Maoquan
    Li, Sidan
    PEDIATRIC TRANSPLANTATION, 2022, 26 (07)
  • [3] Allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: a summary of a 20-year experience
    Zielinska, Patrycja
    Noster, Izabela
    Wieczorkiewicz-Kabut, Agata
    Bialas, Krzysztof
    Koclega, Anna
    Helbig, Grzegorz
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2023, 133 (7-8):
  • [4] Hematopoietic Stem-Cell Transplantation versus Immunosuppressive Therapy in Patients with Adult Acquired Severe Aplastic Anemia: A Cost-Effectiveness Analysis
    Zhang, Meng-Xue
    Wang, Qian
    Wang, Xiao-Qin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 3529 - 3537
  • [5] Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia
    Dietz, Andrew C.
    Lucchini, Giovanna
    Samarasinghe, Sujith
    Pulsipher, Michael A.
    CURRENT OPINION IN PEDIATRICS, 2016, 28 (01) : 3 - 11
  • [6] Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia
    Zhang, Lining
    Li, Jianping
    Liang, Weiru
    Zhang, Xiaoyu
    Chen, Shulian
    Shi, Yuanyuan
    Hao, Mengze
    Zhao, Xiaoli
    Gong, Ming
    Wei, Jialin
    He, Yi
    Jiang, Erlie
    Han, Mingzhe
    Zhang, Fengkui
    Feng, Sizhou
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [7] Comparison of upfront haploidentical hematopoietic stem cell transplantation and salvage haploidentical hematopoietic stem cell transplantation after immunosuppressive therapy in children with acquired severe aplastic anemia - a multicenter study
    Luo, Danqi
    Qu, Yuhua
    Wang, Dao
    Zhang, Benshan
    Sun, Ming
    Xiong, Hao
    Lu, Jun
    Yang, Rui
    Zhao, Mingyi
    Liu, Haiyan
    Jiang, Hua
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research
    Yuan, Meng
    Jia, Chenguang
    Ma, Jie
    Zhang, Man
    Zhu, Guanghua
    Wang, Bin
    Zheng, Jie
    Qin, Maoquan
    Wu, Runhui
    Li, Sidan
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (06): : 1027 - 1036
  • [9] Busulfan for allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia: A retrospective study
    Si, Yingjian
    Luo, Rongmu
    Qin, Maoquan
    Du, Zhenlan
    Zhang, Xiaomei
    Wang, Ya
    Chen, Wei
    Gu, Wenjing
    Xing, Guosheng
    Dou, Lingsong
    Cao, Wei
    Feng, Zhichun
    ACTA HAEMATOLOGICA, 2023,
  • [10] Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study
    Wu, Li-qiang
    Huang, Li-fang
    Yang, Hui
    Ye, Bao-dong
    Sheng, Jian-ping
    Yu, Qing-hong
    Yang, Yan
    Jia, Jin-song
    Zhang, Dong-hua
    Lin, Sheng-yun
    He, Guang-sheng
    Li, Jian-yong
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2015 - 2023